Targeting CLL cells with the VIVIT peptide blocks BCR-mediated NFAT2 activation and target genes in responsive cells (61, 71); at the same time, VIVIT blocks constitutive NFAT activation in CLL, thus rescuing leukemic cells from anergy (77). This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.